Cargando…

Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination

BACKGROUND: Severe side effects after vaccination with coronavirus disease 2019 (COVID‐19) vaccines are rare but can be fatal. To date, vaccine‐induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID‐19 vaccines. Here, we report...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hosseinzadeh, Rezvan, Barary, Mohammad, Mehdinezhad, Hamed, Sio, Terence T., Langer, Florian, Khosravi, Sahar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210570/ https://www.ncbi.nlm.nih.gov/pubmed/35769629 http://dx.doi.org/10.1002/rth2.12750

Ejemplares similares

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022)

BBIBP-CorV: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2022)

Abducense nerve palsy following BBIBP-CorV (Sinopharm) COVID-19 vaccine
por: Khalili, M.R., et al.
Publicado: (2022)

Cord blood antibodies following BBIBP‐CorV (Sinopharm) vaccination during pregnancy
por: Hantoushzadeh, Sedigheh, et al.
Publicado: (2023)

Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
por: Jeewandara, Chandima, et al.
Publicado: (2021)

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
por: Zhang, Yaowen, et al.
Publicado: (2022)

Autoimmune encephalitis after BBIBP-CorV (Sinopharm) COVID-19 vaccination: a case report
por: Vences, Miguel A., et al.
Publicado: (2022)

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine
por: Ferenci, Tamás, et al.
Publicado: (2022)

Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study
por: Gómez de la Torre, Juan C., et al.
Publicado: (2022)

Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Evaluation of SARS-CoV-2 Serum Level in Patients Vaccinated With Sinopharm/BBIBP-CorV With Kidney Transplantation
por: Rahbar, Maryam, et al.
Publicado: (2022)

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
por: Thonginnetra, Saraiorn, et al.
Publicado: (2022)

SG-APSIC1049: Immunogenicity of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in seropositive and seronegative adults
por: Stoma, Igor, et al.
Publicado: (2023)

Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
por: Wang, Chao, et al.
Publicado: (2022)

Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm)
por: Cvetkovic-Vega, Aleksandar, et al.
Publicado: (2023)

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
por: Ali Sahraian, Mohammad, et al.
Publicado: (2021)

Toxic epidermal necrosis following Sinopharm COVID‐19 vaccine (BBIBP‐CorV): A case report and literature review
por: Shakoei, Safoura, et al.
Publicado: (2022)

Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2023)

Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study
por: Stoma, Igor, et al.
Publicado: (2023)

Upper extremity deep vein thrombosis following BBIBP‐CorV COVID‐19 vaccine (Sinopharm vaccine): A case report
por: Riazi, Ali, et al.
Publicado: (2023)

BBIBP-CorV: Hepatitis: case report
Publicado: (2022)

Characterisation of the Antibody Response in Sinopharm (BBIBP-CorV) Recipients and COVID-19 Convalescent Sera from the Republic of Moldova
por: Ulinici, Mariana, et al.
Publicado: (2023)

Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination
por: Zaheri, Hamidreza, et al.
Publicado: (2022)

BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022)

SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study
por: Safarnezhad Tameshkel, Fahimeh, et al.
Publicado: (2023)

BBIBP-CorV: Steven-Johnson syndrome : case report
Publicado: (2022)

BBIBP-CorV: Acute disseminated encephalomyelitis: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson syndrome: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson-syndrome: case report
Publicado: (2022)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023)

SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2022)

BBIBP-CorV/tozinameran: Subacute thyroiditis: 2 case reports
Publicado: (2022)

BBIBP-CorV: Adult multisystem inflammatory syndrome: case report
Publicado: (2021)

BBIBP-CorV: Eye disorders and hypertension: 7 case reports
Publicado: (2021)

Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine
por: Tang, Bo, et al.
Publicado: (2022)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

Sinopharm’s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2
por: Abdelhafiz, Ahmed Samir, et al.
Publicado: (2022)

Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
por: Greish, Khaled, et al.
Publicado: (2022)

The Effect of Disease Modifying Drugs of Multiple Sclerosis on the Effectiveness of BBIBP-CorV COVID19 Vaccine
por: Ghaffari, Mehran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3ccbuoc66hr8qvt3qr7rbb7stf